陕西盘龙药业集团股份有限公司关于公司股票交易异常波动的公告

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days (November 11, 2025, to November 13, 2025) [2] - The company conducted an internal review and confirmed that there were no significant changes in its operational environment and that it had not discovered any undisclosed major information affecting stock prices [3][4] - The board of directors confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange listing rules, and previous disclosures do not require correction or supplementation [4]